Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Opioids: FDA Eyes Better Prescriber Education, But Academics Urge Promotion Crackdown

Executive Summary

US agency is convening two-day workshop on federal efforts to support healthcare provider education about pain management and safe use of the drugs; two University of Washington researchers say agency needs to exercise stricter oversight of opioid marketing and promotion.

Advertisement

Related Content

FDA's Commissioner Fish Story Continues
Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse
Opioids May All Require Mandatory Education As US FDA Expands REMS To Immediate-Release Formulations
Restrictive REMS Is Least Favored Path For Opioid Prescriber Education
Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?

Topics

Advertisement
UsernamePublicRestriction

Register

PS120464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel